Wells Fargo & Co reissued their buy rating on shares of Kala Pharmaceuticals (NASDAQ:KALA) in a research report sent to investors on Friday morning.

Several other equities analysts have also recently commented on the company. BidaskClub upgraded Kala Pharmaceuticals from a strong sell rating to a sell rating in a research note on Friday, December 29th. Wedbush reiterated an outperform rating and set a $46.00 target price on shares of Kala Pharmaceuticals in a research note on Friday, December 22nd. JPMorgan Chase & Co. set a $35.00 target price on Kala Pharmaceuticals and gave the company a buy rating in a research note on Sunday, November 19th. Finally, Zacks Investment Research cut Kala Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, October 17th. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $36.80.

Kala Pharmaceuticals (NASDAQ KALA) traded up $1.35 during trading on Friday, hitting $13.61. The stock had a trading volume of 1,113,420 shares, compared to its average volume of 973,440. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.00 and a quick ratio of 11.00. Kala Pharmaceuticals has a 12 month low of $11.81 and a 12 month high of $26.75.

Kala Pharmaceuticals (NASDAQ:KALA) last released its earnings results on Tuesday, November 7th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.14). analysts forecast that Kala Pharmaceuticals will post -2.22 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the stock. Orbimed Advisors LLC acquired a new stake in shares of Kala Pharmaceuticals during the 3rd quarter valued at approximately $54,251,000. Crestline Management LP acquired a new stake in shares of Kala Pharmaceuticals during the 3rd quarter valued at approximately $888,000. Alyeska Investment Group L.P. acquired a new stake in shares of Kala Pharmaceuticals during the 3rd quarter valued at approximately $2,907,000. JPMorgan Chase & Co. acquired a new stake in shares of Kala Pharmaceuticals during the 3rd quarter valued at approximately $4,037,000. Finally, Caxton Corp acquired a new stake in shares of Kala Pharmaceuticals during the 3rd quarter valued at approximately $12,430,000. 62.96% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Kala Pharmaceuticals (KALA) Earns Buy Rating from Wells Fargo & Co” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.watchlistnews.com/kala-pharmaceuticals-kala-earns-buy-rating-from-wells-fargo-co/1798923.html.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Analyst Recommendations for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.